a small study compared dapagliflozin and teneligliptin in patients with MASLD and found improvements in transaminases and a reduction in body fat only in the group treated with dapagliflozin 49
Heres whats covered in this post: The GLP-1 drugs and muscle loss problem what the data actually shows, and why the internet panic is both overblown and underblown in different ways What myostatin is the protein that limits muscle growth, and why scientists have spent 30 years trying to block it Two drugs, two philosophies apitegromab versus bimagrumab, the precision approach versus the heavy hand, and their very different risk profiles The EMBRAZE trial the most exciting recent result, and the critical finding the headlines skipped A brief word on retatrutide the most powerful GLP-1-class drug yet, and a caution worth noting Why a lean, healthy 34-year-old doctor takes low-dose tirzepatide Dr
Researchers observed no adverse events and documented rapid pharmacokinetic clearance PMID: 40131143
Caveat: Because the available data is weak, borage and milk thistle remain unproven
People with Type 2 diabetes have a higher risk of heart attacks and strokes GLP-1s may help reduce these risks
